目的 探討宣肺止嗽合劑聯(lián)合頭孢地尼治療急性細菌性上呼吸道感染的臨床療效。方法 選取2021年6月—2023年6月上海交通大學醫(yī)學院蘇州九龍醫(yī)院收治的急性細菌性上呼吸道感染患者120例，隨機分為對照組（60例）和治療組（60例）。對照組患者口服頭孢地尼分散片，100 mg/次，3次/d。在對照組的基礎上，治療組口服宣肺止嗽合劑，20 mL/次，3次/d。兩組連續(xù)服藥7 d。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀恢復時間，體溫（T），白細胞計數(shù)（WBC），血清炎性因子白細胞介素-6（IL-6）、降鈣素原（PCT）、干擾素-γ（INF-γ）和C反應蛋白（CRP）水平。結果 治療后，治療組臨床總有效率為98.33%，明顯高于對照組總有效率（83.33%，P＜0.05）。治療后，治療組癥狀好轉時間均明顯短于對照組（P＜0.05）。治療后，兩組患者體溫、WBC、IL-6、PCT、CRP指標水平均比治療前顯著下降，而IFN-γ水平明顯升高（P＜0.05），且治療組這些指標水平均明顯好于對照組（P＜0.05）。結論 頭孢地尼與宣肺止嗽合劑協(xié)同治療急性細菌性上呼吸道感染，可明顯改善患者體溫及癥狀，并能有效減弱上呼吸道炎性反應狀態(tài)。

Objective To explore the clinical effect of Xuanfei Zhisou Mixture combined with cefdinib in treatment of acute bacterial upper respiratory tract infection. Methods Patients (120 cases) with acute bacterial upper respiratory tract infection in Suzhou Jiulong Hospital of Shanghai Jiaotong University School of Medicine from June 2021 to June 2023 were randomly divided into control (60 cases) and treatment (60 cases) group. Patients in the control group were po administered with Cefdinir Dispersible Tablets, 100 mg/time, three times daily. Patients in the treatment group were po administered with Xuanfei Zhisou Mixture on the basis of the control group, 20 mL/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, temperature (T), WBC, the levels of IL-6, PCT, CRP and IFN-γ in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.33%, which was significantly higher than that of the control group (83.33%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the levels of T, WBC, IL-6, PCT and CRP in two groups were significantly lower than those before treatment, while the level of IFN-γ were significantly increased (P < 0.05), and the levels of these indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The synergistic treatment of cefdinib and Xuanfei Zhisou Mixture can significantly improve the patient's body temperature and symptoms, and can effectively reduce the inflammatory state of the upper respiratory tract.

R974